San Shao, Lin Chia-der, Tsai Sheng-Ta, Lin Chao-Chun, Wu Po-Chang
Department Teaching, China Medical University Hospital, Taichung, Taiwan.
Department Otolaryngology , China Medical University Hospital, Taichung, Taiwan.
Arch Rheumatol. 2018 Nov 30;34(2):233-237. doi: 10.5606/ArchRheumatol.2019.7178. eCollection 2019 Jun.
Immunoglobulin G4-related disease (IgG4-RD) is a systemic autoimmune disease; however, it rarely presents as recurrent otitis media and mixed hearing loss. In this article, we present a 43-year-old male patient who presented with recurrent otitis media and mixed hearing loss that is the 12th case of IgG4-RD with middle and inner ear involvement. We also report the clinical response of cyclophosphamide and rituximab therapy in IgG4- RD. These two drugs have never been used to treat otologic symptoms, but were used to treat other organs affected by IgG4-RD. One year later, the patient underwent mastoidectomy of the right ear and the pathological reports revealed IgG4-related disease. A rheumatologist administered immunosuppressive therapy comprising cyclophosphamide and rituximab. After therapy, patient's right-sided mixed hearing loss partially improved. We recorded all pure tone audiometry data to evaluate the clinical course and treatment effect. Finally, we concluded that pathological confirmation and further immunosuppressive therapy should be considered in a timely manner to prevent hearing impairment. We recommend cyclophosphamide and rituximab for the treatment of diseases involving the middle and inner ear.
免疫球蛋白G4相关性疾病(IgG4-RD)是一种全身性自身免疫性疾病;然而,它很少表现为复发性中耳炎和混合性听力损失。在本文中,我们报告了一名43岁男性患者,他表现为复发性中耳炎和混合性听力损失,这是第12例累及中耳和内耳的IgG4-RD病例。我们还报告了环磷酰胺和利妥昔单抗治疗IgG4-RD的临床反应。这两种药物从未用于治疗耳部症状,但用于治疗受IgG4-RD影响的其他器官。一年后,患者接受了右耳乳突切除术,病理报告显示为IgG4相关性疾病。一名风湿病学家给予了包括环磷酰胺和利妥昔单抗的免疫抑制治疗。治疗后,患者右侧混合性听力损失部分改善。我们记录了所有纯音听力测定数据以评估临床过程和治疗效果。最后,我们得出结论,应及时考虑病理确诊和进一步的免疫抑制治疗以预防听力损害。我们推荐环磷酰胺和利妥昔单抗用于治疗累及中耳和内耳的疾病。